James Woodruff Lillie Sells 721 Shares of Maplight Therapeutics (NASDAQ:MPLT) Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) insider James Woodruff Lillie sold 721 shares of the firm’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $28.28, for a total value of $20,389.88. Following the transaction, the insider directly owned 242,729 shares in the company, valued at $6,864,376.12. This trade represents a 0.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

James Woodruff Lillie also recently made the following trade(s):

• On Wednesday, May 6th, James Woodruff Lillie sold 24,811 shares of Maplight Therapeutics stock. The shares were sold at an average price of $28.76, for a total value of $713,564.36.
• On Tuesday, May 5th, James Woodruff Lillie sold 11,095 shares of Maplight Therapeutics stock. The shares were sold at an average price of $28.20, for a total value of $312,879.00.
• On Monday, May 4th, James Woodruff Lillie sold 15,801 shares of Maplight Therapeutics stock. The shares were sold at an average price of $27.96, for a total value of $441,795.96.

Maplight Therapeutics Stock Up 0.7%

Shares of NASDAQ:MPLT opened at $30.30 on Wednesday. The company’s 50-day moving average is $23.54. Maplight Therapeutics, Inc. has a 12-month low of $12.24 and a 12-month high of $33.28. The company has a market capitalization of $1.29 billion and a PE ratio of -0.76.

Maplight Therapeutics (NASDAQ:MPLT) last announced its quarterly earnings data on Thursday, March 26th. The company reported ($2.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.05) by ($1.42). As a group, research analysts expect that Maplight Therapeutics, Inc. will post -3.96 EPS for the current fiscal year.

Hedge Funds Weigh In On Maplight Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Strs Ohio purchased a new position in shares of Maplight Therapeutics during the fourth quarter valued at approximately $53,000. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of Maplight Therapeutics during the fourth quarter valued at approximately $70,000. New York State Common Retirement Fund purchased a new position in shares of Maplight Therapeutics during the fourth quarter valued at approximately $93,000. MetLife Investment Management LLC purchased a new position in shares of Maplight Therapeutics during the fourth quarter valued at approximately $172,000. Finally, Walleye Capital LLC purchased a new position in shares of Maplight Therapeutics during the fourth quarter valued at approximately $205,000.

Analysts Set New Price Targets

A number of analysts have recently weighed in on MPLT shares. Weiss Ratings started coverage on shares of Maplight Therapeutics in a report on Thursday, January 22nd. They set a “sell (e)” rating for the company. HC Wainwright started coverage on shares of Maplight Therapeutics in a report on Monday, May 4th. They set a “buy” rating and a $45.00 target price for the company. TD Cowen began coverage on shares of Maplight Therapeutics in a research note on Tuesday, April 7th. They issued a “buy” rating for the company. Canaccord Genuity Group began coverage on shares of Maplight Therapeutics in a research note on Thursday, March 19th. They issued a “buy” rating and a $35.00 price target for the company. Finally, Needham & Company LLC began coverage on shares of Maplight Therapeutics in a research note on Wednesday, April 8th. They issued a “buy” rating and a $37.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $34.43.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.